Pegvisomant

Limits on what this shows

• Key negative/null findings: Direct pegvisomant-and-mitochondria searches (two phrasings) returned zero indexed PubMed results as of this review.
• At-risk subgroups: None defined.

Regulatory status

Not addressed in labeling.

Population evidence

Brioche T, Kireev RA, Cuesta S, et al. J Gerontol A Biol Sci Med Sci. 2014;69(10):1186-98. Rat model (Tier B, mechanistic animal study): GH replacement in old, GH-deficient rats improved markers of mitochondrial biogenesis and antioxidant defenses. This is GH replacement, not GH-receptor antagonism, and not pegvisomant - the opposite pharmacological direction, so it is treated as Tier C extrapolation for this drug.

Mechanism

Named. GH/IGF-1 signaling through PI3K/Akt and PGC-1α is an established driver of mitochondrial biogenesis in several tissues; GH-receptor blockade would be expected, in principle, to act opposite to a GH-replacement effect.

Counter-evidence held on record

Counter-evidence None identified that specifically opposes the pathway reasoning; the core uncertainty is that reverse-inference from a GH-replacement study to a GH-receptor antagonist has never itself been tested. Framing caution: this entry rests entirely on animal data running in the opposite pharmacological direction plus general pathway biology. It is not evidence that pegvisomant impairs mitochondrial function in treated patients; treat as theoretical only.

Limits on what this shows

• Key negative/null findings: A direct "pegvisomant AND oxidative stress" PubMed search returned zero indexed results as of this review.
• At-risk subgroups: None defined.

Regulatory status

Not addressed in labeling.

Population evidence

Brioche T, et al. J Gerontol A Biol Sci Med Sci. 2014;69(10):1186-98 (same source as the mitochondrial burden entry; see overlap map). GH replacement improved antioxidant defense markers in aged, GH-deficient rats. Tier C for pegvisomant (wrong drug, wrong direction).

Mechanism

Named, theoretical only. GH/IGF-1 signaling is linked to antioxidant enzyme expression in animal models; a GH-receptor antagonist could theoretically work against this, but this has not been measured in pegvisomant-treated patients.

Counter-evidence held on record

Counter-evidence None specific to pegvisomant; the direction problem noted above (GH replacement vs. GH-receptor blockade) is itself the main caution against over-reading this entry. Framing caution: theoretical extrapolation only, from an animal study of the opposite intervention. No pegvisomant-treated human oxidative-stress data exist.

Limits on what this shows

• Why no grade: Both Step 7 conditions are met: no Tier B/C evidence exists to support even a yellow grade, and no circulating consumer claim was found to rebut as white. Two search phrasings were run against PubMed's search-listing pages: "growth hormone copper ceruloplasmin" (11 results reviewed, all concerning unrelated genetic disorders, cell-line biology, or veterinary copper deficiency, none touching acromegaly or pegvisomant) and "acromegaly trace elements zinc copper serum" (this second attempt was blocked by proxy rate-limiting and could not be completed). This is disclosed as a genuine dual limitation: one substantive null result plus one blocked attempt, rather than a single blocked attempt standing in for the whole category.

Tooling note

The blocked second attempt reflects session-level HTTP 429 rate-limiting encountered repeatedly across PubMed, Europe PMC, Semantic Scholar, Crossref and OpenAlex during this review, not a decision to stop searching after one try. A later revision with fresh tooling access should re-attempt the trace-element angle.

Limits on what this shows

• Why no grade: Both Step 7 conditions are met. Three phrasings were run: "growth hormone IGF-1 iron metabolism hepcidin" (zero indexed PubMed results), "acromegaly iron deficiency anemia" (blocked by a bot-verification challenge on that attempt), and "growth hormone receptor iron homeostasis" (23 results reviewed across the returned page; none addressed GH receptor signaling's relationship to iron homeostasis, ferritin, transferrin, or hepcidin - the closest hits concerned FGF23/phosphate biology and prolactin-driven iron release in an unrelated cancer model). No circulating consumer claim about pegvisomant and iron was identified via the channels available.

Tooling note

One of the three attempts was blocked by bot-verification rather than returning a genuine null result; the other two are genuine, substantive null/irrelevant-result searches, satisfying the "more than one phrasing" thoroughness requirement before settling on ungraded.

Limits on what this shows

• Key negative/null findings: No pegvisomant-specific microbiome study was located.
• At-risk subgroups: None defined.

Regulatory status

Not addressed in labeling.

Population evidence

Jensen EA, Young JA, Mathes SC, et al. Growth Horm IGF Res. 2020. Review, "Crosstalk between the growth hormone/insulin-like growth factor-1 axis and the gut microbiome" (Tier C, review, not pegvisomant-stratified). Yan J, Herzog JW, Tsang K, et al. Proc Natl Acad Sci U S A. 2016;113(47):E7554-63 (Tier B, mouse model): gut microbiota colonization increases serum IGF-1 and promotes bone formation - this is the microbiome driving IGF-1, the reverse of the direction this entry would need to support a drug-caused microbiome effect.

Mechanism

Bidirectional crosstalk between the GH/IGF-1 axis and the gut microbiome is established in animal models, but the evidence base is stronger for the microbiome affecting IGF-1 than for the reverse. Applying it to "pegvisomant changes the microbiome" is an inference from pathway biology, not a direct finding.

Counter-evidence held on record

Counter-evidence / direction check Per Hard Rule 4, the direction of the cited relationship runs mostly microbiome-to-hormone, not hormone-to-microbiome; this is disclosed rather than presented as if pegvisomant were shown to alter the microbiome. Framing caution: included because Step 3 requires evaluating this category for every drug, not because strong direct evidence supports a pegvisomant-to-microbiome effect. Treat as a research gap, not a finding.

Limits on what this shows

• Key negative/null findings: The Zoppoli source's own attribution to secondary causes functions as a partial counter-finding against a direct GH-to-hematocrit mechanism.
• At-risk subgroups: None defined for pegvisomant specifically; if acromegaly-associated polycythemia exists at all, sleep-apnea comorbidity appears to be the stronger driver per the cited source.

Regulatory status

Not addressed in labeling; no hematologic monitoring is required by the SOMAVERT label.

Population evidence

Zoppoli G, Bianchi F, Bruzzone A, et al. Pituitary. 2012;PMID 21503687. Single-center epidemiological case series of acromegaly patients with polycythemia (Tier C for pegvisomant: acromegaly cohort, treated with octreotide LAR in the description available, not pegvisomant-stratified).

Mechanism

Contested. GH/IGF-1 can in principle stimulate erythropoietin and erythropoiesis, but the cited source attributes most acromegaly-associated polycythemia to secondary/confounding causes rather than a direct hormonal effect.

Counter-evidence held on record

Counter-evidence Confounding by comorbid sleep apnea and rare EPO-secreting tumors is presented in the source itself as the more likely explanation for acromegaly-associated polycythemia, weakening a direct causal story before pegvisomant is even considered. Framing caution: this is weak, contested, disease-level (not drug-level) evidence. No pegvisomant-specific hematologic data exist in either direction; do not read this as evidence that pegvisomant lowers or raises hematocrit.

Limits on what this shows

• Key negative/null findings: None identified; the direction is consistent with expected pharmacology of GH-receptor blockade in a previously hypermetabolic population.
• At-risk subgroups: Exact cohort size and full study design could not be confirmed beyond the quoted result, because the article's direct page was not reachable during this review (see access note); disclosed as a limitation.

Regulatory status

Not addressed in labeling as an energy-metabolism warning.

Population evidence

Lindberg-Larsen R, Møller N, Schmitz O, Nielsen S, Holst JJ, Jørgensen JOL. J Clin Endocrinol Metab. 2007. Pegvisomant-cohort interventional study (Tier A: this drug directly in the studied population) reporting total resting energy expenditure decreased after pegvisomant treatment: 1703 ± 109 vs. 1563 ± 101 kcal/24h (P = 0.03).

Mechanism

Named. GH/IGF-1 excess raises resting energy expenditure and lipolysis in acromegaly; blocking the GH receptor and normalizing IGF-1 reduces this toward the normal range.

Counter-evidence held on record

Hard Rule 2 note Reduced whole-body resting energy expenditure here is the drug's own intended pharmacologic effect: reversing acromegaly's GH/IGF-1-driven hypermetabolic state. It is graded yellow, not orange or red, specifically because it is a disease-normalization signal, not a nutrient-driven energy deficit, and it is the closest measured proxy available for the required "ATP production" category rather than a literal mitochondrial ATP synthesis measurement. Framing caution: do not use this finding to suggest energy-support supplementation. A falling resting energy expenditure toward normal in a previously hypermetabolic acromegaly patient is a treatment-response marker, not a deficiency to correct.